You just read:

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Sep 09, 2019, 08:00 ET